Mankind Pharmaceuticals has inked a licensing pact with Glenmark Pharmaceuticals to co-market diabetes drug Remogliflozin Etabonate in the country. Under the sub-licensing agreement, Mankind will market the drug under its own trademark while Glenmark will manufacture and supply it to the drug firm.
This is particularly important in reducing overall disease burden. Moreover, this strategic decision will not only strengthen Mankind Pharma’s diabetes portfolio but also help consolidate its position as the fastest-growing player in the anti-diabetes segment.
Glenmark Pharmaceuticals is a global pharmaceutical company. The company is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Its segments are India, United States, Latin America, Europe and Rest of the World (ROW).
